By Darrin LaVelle, Founder of RENVA Health
Last updated: July 3, 2026
Short answer: the FDA doesn't legally require any specific lab tests before starting a GLP-1 medication — but major medical guidelines recommend a standard baseline panel anyway, and a provider skipping labs entirely isn't necessarily following best practice just because it's technically not required.
If you're comparing providers and notice some require bloodwork before prescribing while others don't, this explains what's actually behind that difference — what the FDA does and doesn't mandate, what clinical guidelines recommend regardless, and why the distinction matters for your safety, not just as a procedural hoop to jump through.
Here's something that surprises a lot of people: the prescribing information for Wegovy, Zepbound, and Foundayo lists indications, dosing, contraindications, and warnings in detail — but none of them specify a mandatory lab panel that must be completed before starting treatment. The FDA leaves that decision to clinical judgment, guided by relevant disease-specific guidelines (like diabetes or cardiovascular risk management), rather than setting a GLP-1-specific lab requirement.
This is an important distinction to understand: "not FDA-required" doesn't mean "not recommended."It means the FDA isn't the body making this particular call — professional medical societies are, and they've been fairly consistent about what they recommend.
Medical guidance synthesizing endocrine and diabetes association recommendations points to a standard set of baseline tests, even though no single test is universally mandated. At minimum, most guidance points to three: HbA1c, kidney function (through a metabolic panel), and a lipid panel. A broader recommended panel often includes:
This checks kidney function (creatinine and eGFR), electrolytes, and baseline blood sugar. It matters specifically because GLP-1 medications can cause gastrointestinal side effects that lead to dehydration, and dehydration can affect kidney function — having a baseline makes it possible to tell whether kidney values have shifted during treatment, and why.
This documents your baseline blood sugar control over the past several months, helps confirm or rule out diabetes or prediabetes, and establishes a marker to track how your blood sugar responds to treatment over time.
This checks cholesterol and triglycerides, both to document baseline cardiovascular risk and because GLP-1 medications often improve these numbers — having a starting point lets you and your provider actually see and track that improvement, not just assume it's happening.
Often recommended, particularly if there's any suspicion of fatty liver disease, since baseline liver values help identify any pre-existing liver issues and provide context if anything changes during treatment.
Not universally mandated, but considered a sensible addition, especially for anyone with a personal thyroid history. It's worth being clear about what this test can and can't tell you: a TSH test doesn't directly screen for medullary thyroid carcinoma, the specific cancer type behind the boxed warning on these medications. What it can do is flag other thyroid conditions and support a broader conversation about thyroid health and family history — which is really where the MTC risk conversation needs to happen, through direct family history questions, not a blood test.
It would be easy to read a list of lab tests and think of it as bureaucratic box-checking. It isn't. Each of these tests exists to catch something that could meaningfully change whether — or how — you should be treated:
A provider skipping all of this isn't necessarily doing anything illegal — but they are skipping a step that professional medical guidance consistently recommends, and that omission is worth knowing about and factoring into your decision, not something you'd necessarily notice was missing on your own.
Getting baseline labs is only part of the picture — ongoing monitoring while on treatment follows a similar "guided by clinical context, not mandated by the drug" pattern.
Typical ongoing monitoring, based on standard diabetes and obesity care protocols, includes:
Beyond this baseline schedule, additional labs are typically ordered only when something specific comes up — pancreatic enzyme testing if pancreatitis is suspected, liver testing or imaging if gallbladder symptoms appear, or thyroid evaluation if relevant symptoms or family history surface during treatment. Weight, BMI, waist circumference, and blood pressure are generally tracked at each visit regardless of lab schedule, since these are the most direct measures of how treatment is progressing.
Telehealth prescribing guidance is explicit on this point: remote care is supposed to meet the same clinical standard as in-person care, including ordering labs when clinically indicated — not skipping them simply because the visit happens over video instead of in an exam room. Labs can be coordinated through a local lab facility even when the visit itself is virtual, so "telehealth" and "no labs required" aren't the same thing, even though some providers structure their offerings that way.
Professional guidance is fairly direct that prescribing GLP-1 medications with zero baseline labs risks missing undiagnosed diabetes, kidney disease, or liver disease — and that skipping this step generally isn't considered best practice, regardless of whether the visit was virtual or in-person.
Given how much this varies between providers, it's worth asking directly:
None of these questions have a universally "right" answer — a provider requiring more testing isn't automatically better, and one requiring less isn't automatically cutting corners — but understanding what's actually being checked (or not checked) is part of making an informed choice.
Q: Is it unsafe to start a GLP-1 medication with zero labs?
It's not automatically dangerous for everyone, but it does mean skipping a step that professional medical guidance consistently recommends, which could mean an undiagnosed condition (like early kidney disease or diabetes) goes unnoticed longer than it otherwise would.
Q: Will insurance cover the cost of these labs?
This varies by insurance plan and by whether the labs are billed as routine preventive care or as part of a specific evaluation. It's worth checking with your specific plan and provider.
Q: Can I bring my own recent labs instead of getting new ones?
Many providers will accept recent labs (often within the last 3–12 months, depending on the specific test and provider policy) rather than requiring everything to be redone — worth asking directly.
Q: Does a normal TSH test rule out thyroid cancer risk?
No — TSH testing doesn't directly screen for medullary thyroid carcinoma, the specific concern behind the boxed warning. That risk is assessed primarily through personal and family history, which is why disclosing that history accurately matters more than any single blood test.
Q: How often will I need labs once I'm on treatment?
This depends on your individual situation, but common patterns include blood sugar testing every 3–6 months and periodic kidney function and lipid testing, with additional tests only if specific symptoms or concerns arise.
See also: How to Get Prescribed a GLP-1 Medication for the full evaluation and prescription process, and Who Qualifies for GLP-1 Medications? for the complete contraindications and candidacy criteria.
Medical disclaimer: RENVA is not a healthcare provider. This article is informational and educational only. It does not constitute medical advice, diagnosis, or a prescription. Always consult a licensed healthcare professional before making health decisions. Full medical disclaimer →
Answer a few preference questions — budget, labs, provider model, and cancellation flexibility. Preference-based and informational only.
Take the free quizWhat it actually takes to get prescribed Wegovy, Zepbound, or another GLP-1 medication — eligibility criteria, the evaluation process, insurance steps, and realistic timelines.
A complete breakdown of who qualifies for GLP-1 weight-loss medications, who doesn't, and the specific contraindications and special-population considerations behind the FDA criteria.
A clear look at GLP-1 side effects — from common nausea to rare but serious risks — based on FDA labeling and adverse event data, plus what tends to help.